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higher in patients treated with conventional radiotherapy. OS at 2 and 
5 years for the accelerated radiotherapy group were 16% and 3%, 
respectively, and 44% and 19% for the conventional radiotherapy group 
(P<0.00001). However, there was no statistical difference in LRC, 
DFS and DMFS between the two groups. LRC at 2 and 5 years for the 
accelerated radiotherapy group were 47% and 19%, compared to 48% 
and 37% for the conventional radiotherapy group. DFS at 2 and 5 years 
for the accelerated group were 24% and 10%, 30% and 19% for the 
conventional radiotherapy group. In terms of toxicity, 12 patients (11%) 
had Common Toxicity Criteria for Adverse Events (CTCAE) grade 3 or 
more treatment related pneumonitis. 6 patients (5%) had CTCAE grade 
3 acute esophagitis and only 1 patient had RTOG grade 3 late esopha-
geal toxicity.
Conclusions: In spite of treating the patients with poorer PF, acceler-
ated radiotherapy of 45 Gy in 15 fractions over 3 weeks achieved com-
parable local-regional control for Stage III NSCLC with conventional 
radiotherapy. Toxicity of accelerated radiotherapy was acceptable. 
Accelerated radiotherapy is reasonable strategy for patients who have 
locally advanced NSCLC with unfavorable prognostic factors, since 
their main goal of treatment is to improve their quality of life within a 
limited time. 
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Background: The diagnostic yield of TBNA can be highly variable, 
with a meta-analysis reporting the pooled sensitivity and speciﬁcity to 
be only 39% and 99%, respectively. Nodal position is often estimated 
from the distance between the carina and a visible lymph node, as mea-
sured on a diagnostic CT scan. However, breath-hold conventional CT 
scans do not account for nodal motion, and nodal motion may explain 
the lower yields when TBNA is performed without real-time ultrasound 
imaging. We studied mediastinal nodal motion on 4-dimensional (4D) 
CT scans.
Methods: A total of 47 distinct mediastinal nodes were identiﬁed on 
4DCT scans performed for radiotherapy planning in 25 patients with 
lung cancer. Nodes were mainly located at station 4R, 4L, 7 and 2R and 
each identiﬁed node was contoured in all 10 phases of the 4DCT. Nodal 
motion was derived from the displacement of the center of mass in the 
respiratory phases. In order to evaluate whether the distance between 
the center of mass of each node and the carina remained constant dur-
ing the respiratory cycle, this distance was derived for all respiratory 
phases using the coordinates of both structures. 
Results: The mean nodal diameter was 10.2 ± 4.0 mm (1SD) and mean 
nodal volume 1.8 ± 2.3 cc. Mobility was maximal in the cranio-caudal 
axis (mean of 4.7 ± 2.3 mm) and the corresponding medio-lateral and 
ventro-dorsal mobility was 2.8 ± 1.9 mm and 2.4 ± 1.8 mm, respec-
tively. The mean 3-dimensional displacement of nodal center was 6.2 ± 
2.9 mm, and this exceeded 10 mm in 5 nodes (Table 1). The nodal mass 
was constantly present in only 25 ± 14% of the region encompassing all 
nodal positions. The mean variation in cranio-caudal distance between 
all nodes and carina position during respiration was 5.3 ± 2.1 mm 
(range 2.2-10.5 mm). 
Conclusions: Both nodal motion and the varying distance between 
carina and nodal position, may explain the lower diagnostic yields for 
TBNA procedures performed without real-time guidance.
Table 1: Three-dimensional nodal mobility per location studied
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Background: Stereotactic Body Radiation Therapy (SBRT) has 
emerged as a non-invasive treatment option for unresectable early stage 
non-small cell lung cancer (NSCLC), delivering very high radio-abla-
tive doses of RT to the primary tumor. To ensure efﬁcacy of treatment 
and patient safety, high precision planning and careful treatment deliv-
ery under vigilant quality assurance are needed. We present the evolu-
tion of SBRT practice at Princess Margaret Hospital with an emphasis 
on accuracy of treatment set up and veriﬁcation using image-guided 
techniques.
Methods: From Oct 2004 to Feb 2007, we treated 46 patients (pts) 
with T1T2N0MO NSCLC with SBRT (48 tumors were treated). RT 
schedule for peripheral tumors was 60 Gy/3 fractions over 2 weeks (for 
29 tumors, 12 of the pts were part of the RTOG 0236 phase II study). 
When organ at risk tolerance doses were not achievable, either 54 
Gy/3 fr (3 pts) or 48 Gy/4 fr (10 tumors, all T1) was employed. Central 
tumors were treated with a lower dose of 50 Gy/10 fr schedule (6 pts). 
4DCT simulation was acquired in all but 9 pts who were too large for 
the scanner. All tumor and normal tissue contours and ﬁnal plans are 
reviewed in weekly multidisciplinary SBRT rounds. On the treatment 
unit, cone beam CT (CBCT) is used for image guidance with therapist 
manually matching directly to the tumor, adjusting the patient’s posi-
tion for discrepancies >3mm. CBCT is performed for initial localiza-
tion and repeated during treatment to verify the tumor position. We 
compared CBCT soft tissue (tumor) matching to bone matching (which 
would mimic matching used in conventional portal imaging). Patients 
are followed every 3 months with radiological and clinical assessment.
Results: Median pt age was 73 yrs (48-96); mean tumor size was 2.6 
cm (range 0.7-5.7). Median follow-up is 10 mo (range 0-26 mo). Acute 
RT toxicity was generally mild with grade G1 fatigue the most common 
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acute side effect (16 pts). There was 1 episode of G3 dyspnea possibly 
treatment related, but no other >G2 events. One pt developed G2 RT 
pneumonitis. 9 pts developed late chest pain at 3-21 mo post SBRT; 
4 of those developed rib fractures in the RT ﬁeld area, 11-21 mo post 
SBRT. In 38 evaluable pts (40 tumors), 6 CR and 24 PR were observed. 
There were no local failures in 36 pts with peripheral tumors, but 2 fail-
ures in pts treated with the lower 50 Gy/10 fr schedule. CBCT tumor 
matching compared to bone matching resulted in a mean difference of 
6.8mm (±4.9), the difference was >13.9 mm in 10% of pts; this would 
have resulted in very signiﬁcant tumor miss if portal imaging was used 
without proper visualization of the target. 
Conclusion: These results conﬁrm that lung SBRT gives high rates 
(95%) of local control with the only local failures observed in the 
centrally-located tumors treated with lower dose of 50 Gy/10 fr. Acute 
toxicity is low; rib fracture is the most common late toxicity. CBCT 
greatly improves the accurate delivery of high radioablative doses of 
SBRT for early stage lung cancer.
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Phase I/II results of RTOG L-0117; a phase I/II dose intensification 
study using 3DCRT and concurrent chemotherapy for patients 
with inoperable NSCLC
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Background: The standard radiation dose for NSCLC was established 
by RTOG 7301 as 60 Gy. Local failure rates with this dose remain 
unacceptably high. In preparation for a anticipated Phase III compari-
son of high dose versus standard dose radiation therapy, this Phase I/II 
study was initiated to establish the maximum tolerated dose (MTD) 
of radiation therapy, in the setting of concurrent chemotherapy, using 
3DCRT for NSCLC. 
Methods: Eligibility included patients with histologically proven, unre-
sectable Stages I-III NSCLC and a Zubrod perfomance status of 0-1. 
Weight loss eligibility was <10%. Concurrent chemotherapy consisted 
of paclitaxel 50 mg/m2 and carboplatin AUC=2 given weekly. Radia-
tion (RT) dose was started at 75.25 Gy/35 fractions. Once the MTD 
was reached, the phase II portion of the study was initiated and contin-
ues to accrue. Radiation therapy volumes consisted of gross tumor and 
nodes plus a margin. Elective lymph nodes were not included in the 
treatment ﬁelds. Technical criteria included strict dosimetric constraints 
on the normal lung (V20 <30%) and esophagus (mean dose <34 Gy 
and V55 < 30%) and water-based dose calculations prescribed to the 
isocenter.
Results: The Phase I portion of this study accrued 17 patients from 8 
institutions and was closed in January 2004. After the initial 8 patients 
were accrued to Arm 1, the trial closed temporarily on September 
26, 2002 due to reported toxicity. Two acute treatment-related DLTs 
were reported: a grade 5 infection/febrile neutropenia and a grade 3 
pneumonitis. The protocol, therefore, was revised to de-escalate the 
RT dose (74 Gy/37 fractions). Arm 2 accrued 9 patients with 2 (22%) 
developing Grade 3 GI toxicities and 1 (11%) reporting a Grade 3 in-
fection/febrile neutropenia. Phase II has accrued 31 eligible patients at 
74 Gy. Of the 27 (87%) patients with acute toxicity information, there 
were 3 (11%) Grade 3 pain toxicities, 2 (7%) Grade 3 infection/febrile 
neutropenia toxicities, 1 (4%) Grade 3 pulmonary toxicity, and 1 (4%) 
Grade 3 skin toxicity. A total of 13 (48%) patients reported grade 3+ 
non-hematologic toxicities.
Conclusions: The MTD was determined to be 74 Gy/37 fractions (2.0 
Gy per fraction) using 3DCRT with concurrent paclitaxel and carbo-
platin. Four (11%) grade 3 pulmonary or infection/febrile neutropenia 
toxicities have occurred at the 74 Gy dose level. The Phase II compo-
nent of RTOG L-0117 will close with the opening of our Phase III trial 
(RTOG 0617).
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Local therapy of primary diseae improves survival in non-small 
cell lung cancer metastatic to a single organ - a lesson from brain 
metastases
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Introduction: The standard therapy for non-small cell lung cancer 
(NSCLC) brain metastases involves radiotherapy and/or surgical 
resection for all visible lesions. This practice has been based on the 
assumption that brain metastases are less sensitive to systemic therapies 
and has been shown to palliate brain metastasis-related symptoms and 
to improve survival. Similarly, we hypothesize that additional local 
therapy for other sites of disease, particularly the primary tumor and 
locoregional lymph node metastases, may further improve survival. 
Methods: Patients with metastatic NSCLC who received ablative 
local therapy of primary disease - radiotherapy (≥ 45 Gy) or surgical 
resection of their primary tumor and locoregional lymph nodes - tend to 
have a low volume of disease prior to treatment. To identify those who 
received this deﬁnitive local therapy, we searched the M.D. Anderson 
Cancer Center Tumor Registry, Thoracic Radiation Oncology, and Neu-
rosurgery databases, for patients with only one organ site of metastasis 
and analyzed their overall survival based on deﬁnitive local therapy of 
primary disease and the presence or absence of brain metastases. 
Results: 120 patients had brain as a solitary organ site of metastases; of 
them 115 (96%) received local therapy for brain metastases - surgical 
resection, stereotactic radiosurgery, and/or whole brain radiotherapy. 
Of these 120, 10 (8%) also received ablative local therapy of primary 
disease - 8 (6%) with radiotherapy ≥ 45 Gy or 2 (2%)with surgical 
resection of primary tumor and locoregional lymph nodes. Another 
221 patients had a solitary organ site of metastasis outside the brain; of 
them 61 (28%) received local palliative radiotherapy for metastases. 
Of these 221, 35 (16%) also received ablative local therapy of primary 
disease - 33 (15%) with radiotherapy ≥ 45 Gy or 2 (1%) with surgical 
resection of primary tumor and locoregional lymph nodes. In those 
with brain as a solitary organ site of metastasis and single metasta-
sis, there was a marked improvement in survival with resection or 
radiotherapy ≥ 45 Gy for primary thoracic disease (p=0.00186, median 
survival 30 vs. 7 months). In those with non-CNS solitary organ sites 
of metastases, there is only a tendancy towards improved survival in 
